Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer...
-
REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. (“Zumutor”), an immuno-oncology biotech company, today announced a clinical...
-
GAINESVILLE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- X-tosis Receives Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Novel Parkinson's Disease Therapy. The ward...
-
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage...
-
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to...
-
SUDBURY, Ontario, June 22, 2026 (GLOBE NEWSWIRE) -- Magna Mining Inc. (TSXV: NICU) (OTCQX: MGMNF) (FSE: 8YD) (“Magna” or the “Company”) is pleased to provide the results of ongoing exploration and...
-
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
-
Sarclisa de Sanofi en formulation sous-cutanée approuvé au Japon pour les patients atteints de myélome multiple
-
Sydney, Australia, June 18, 2026 (GLOBE NEWSWIRE) -- Australia's retiree population continues to grow. Around 4.4 million Australians are now aged 65 and over. That's about 17% of the population,...
-
OCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final subject has received their first dose in the Phase 2...